Avicanna's SMGH Subsidiary Achieves First Commercial Export to Australia
In a significant milestone for the global medical cannabis industry, Avicanna Inc., a biopharmaceutical company specializing in plant-derived cannabinoid-based products, has announced that its majority-owned subsidiary, Santa Marta Golden Hemp SAS (SMGH), has completed its first commercial export of organic certified cannabis flower to Australia. This export, which occurred on March 26, 2026, marks a pivotal expansion into the Australian market, representing the 21st international market for SMGH and the 24th for all Avicanna products globally.
Strategic Investments and Operational Excellence
Over the past two years, Avicanna has made substantial investments in process development, infrastructure, and quality systems to align SMGH's operations with stringent international regulatory standards for active pharmaceutical ingredients (API) and raw materials. These efforts have positioned SMGH to produce consistent, standardized cannabis flower at a commercial scale, with a strong emphasis on cannabinoid-specific chemotypes, traceability, and compliance with Good Agricultural and Collection Practices (GACP) and organic certification standards.
SMGH's operational model leverages several key structural advantages:
- Year-round cultivation enabled by equatorial conditions in Colombia.
- Controlled environmental parameters to ensure product quality.
- Established genetic portfolios registered in Colombia, supporting batch uniformity and cost efficiencies.
These factors are critical for long-term participation in international medical cannabis markets, where consistency and regulatory adherence are paramount.
Expanding Global Footprint and Proprietary Cultivars
The export to Australia includes SMGH's proprietary CBG cultivar, which is part of Avicanna's portfolio of registered varieties. This shipment underscores the company's growing global presence, with SMGH now supplying products into 21 international markets and Avicanna products reaching 24 markets worldwide. This expansion reflects Avicanna's expertise in navigating complex regulatory frameworks across different jurisdictions, ensuring compliance with all applicable laws.
The Aureus™ brand, Avicanna's line of raw materials and API, including CBD, CBG, and THC manufactured through SMGH, plays a central role in this supply chain. These materials serve as reliable inputs for the company's consumer retail, medical cannabis, and pharmaceutical preparations globally.
Certifications and Production Capacity
SMGH has achieved significant certifications, including GACP and Organic certifications under the United States Department of Agriculture National Organic Program (USDA) for its hemp cultivars. Prior to this commercial export, SMGH had already exported Aureus™ branded products into 20 different countries for research and manufacturing purposes, demonstrating its established track record in the industry.
The SMGH facility boasts approximately 300,000 square feet of cultivation space, with an extraction capacity of 300 kg and an annual yield of around 26,400 kg. This robust infrastructure supports SMGH's commitment to providing consistent, high-quality input materials to various companies operating in diverse industries internationally.
This first commercial export to Australia not only highlights Avicanna's strategic growth but also reinforces its position as a leader in the biopharmaceutical sector, dedicated to advancing medical cannabis through innovation and compliance.
